Huntingdon Life Sciences has acquired Harlan Laboratories, a privately held provider of general and specialty toxicology services. The new company will have two operating divisions: Research Models and Services and Contract Research Services.
This acquisition creates a global organization offering full-service, non-clinical, contract research and research models and services. The increased scale of the combined venture, approaching half a billion dollars in annual revenue, provides a strong platform for future growth and investment.
Brian Cass, CEO of Huntingdon Life Sciences, said, "This acquisition is precisely in line with our strategy to broaden our support for the pharmaceutical, crop protection and chemical industries, as well as universities, government and other research organizations.”